Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Myocardial Infarction
  • Platelet Aggregation Inhibitors
  • Thrombolytic Therapy

abstract

  • Abciximab facilitates the rate and extent of thrombolysis, producing early, marked increases in TIMI 3 flow when combined with half the usual dose of alteplase. This improvement in reperfusion with alteplase occurred without an increase in the risk of major bleeding. Substantial reductions in heparin dosing may reduce the risk of bleeding even further. Modest improvements in TIMI 3 flow were seen when abciximab was combined with streptokinase, but there was an increased risk of bleeding.

publication date

  • June 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10351964

Additional Document Info

start page

  • 2720

end page

  • 32

volume

  • 99

number

  • 21